An Ozempic injection pen on April Martin’s kitchen table on March 14, 2025. Semaglutide (GLP-1) drugs like Ozempic are designed to treat type 2 diabetes, but are widely known for their effect on ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Mounjaro (tirzepatide) will be available in the market from the end of May 2025BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zu ...

Because people need to use syringes rather than an auto-injector pen, they may run the risk of overdosing, which is “extremely unpleasant and could land someone in the hospital,” he says.

Questions arise over Benjamin Ritchie's execution in Indiana. Defense attorneys report unexpected movement during the lethal injection process.

Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter</p ...

‘There are still people out there calling me anti-vax – but I’m not,’ she emphasises. ‘I never have been. I had all my ...

The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted ...

Following the lead of its chief competitor, the state’s second-largest health insurer is significantly scaling back its coverage of costly GLP-1 drugs when used for weight loss beginning next year.

It is administered via a once-weekly injection, typically in the abdomen, thigh or upper arm, using a prefilled injection pen. It works by increasing the levels of incretins, the gut hormones produced ...

In Japan, for instance, the monthly price for a 10 milligram Zepbound injection pen is $61.68. The trade-off is that some drugs are not covered under the government-run plans. In the UK ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.